142 related articles for article (PubMed ID: 19242101)
1. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Correale P; Tindara Miano S; Remondo C; Migali C; Rotundo MS; Macrì P; Tagliaferri P; Caraglia M; Gotti G; Francini G
Cancer Biol Ther; 2009 Mar; 8(6):497-502. PubMed ID: 19242101
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
4. Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study.
Syrigos KN; Karapanagiotou E; Charpidou A; Dilana K; Dannos I; Dionellis G; Rigopoulou A; Georgatou N; Roussos C
J Chemother; 2007 Aug; 19(4):438-43. PubMed ID: 17855189
[TBL] [Abstract][Full Text] [Related]
5. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Georgoulias V; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Palamidas P; Vlachonikolis I;
Lancet; 2001 May; 357(9267):1478-84. PubMed ID: 11377599
[TBL] [Abstract][Full Text] [Related]
6. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Hejna M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger WC; Marosi L; Schneeweiss B; Greul R; Scheithauer W
Cancer; 2000 Aug; 89(3):516-22. PubMed ID: 10931450
[TBL] [Abstract][Full Text] [Related]
8. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group.
Katakami N; Takiguchi Y; Yoshimori K; Isobe H; Bessho A; Yoshimura A; Niitani H
J Thorac Oncol; 2006 Jun; 1(5):447-53. PubMed ID: 17409898
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
J Thorac Oncol; 2006 Jul; 1(6):545-50. PubMed ID: 17409915
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Karapanagiotou EM; Charpidou A; Tzannou I; Dilana K; Kotteas E; Tourkantonis I; Kosmas E; Provata A; Syrigos K
Med Oncol; 2008; 25(3):303-8. PubMed ID: 18204976
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Erland JB; Barton JH; Thompson DS; Stagg MP; Bradof JE; Twele TW; Greco EA;
Clin Lung Cancer; 2003 Jul; 5(1):33-8. PubMed ID: 14596701
[TBL] [Abstract][Full Text] [Related]
14. Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature.
Gridelli C; Frontini L; Barletta E; Rossi A; Barzelloni ML; Scognamiglio F; Guida C; Gatani T; Fiore F; De Bellis M; Marfella A; Manzione L
Anticancer Res; 2000; 20(2B):1077-84. PubMed ID: 10810400
[TBL] [Abstract][Full Text] [Related]
15. Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study.
Syrigos KN; Konstantinou M; Sepsas E; Papamichales G; Loullias A; Belenis I; Skottis I; Charpidou A; Roussos C
Anticancer Res; 2007; 27(4C):2887-92. PubMed ID: 17695466
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Fidias PM; Dakhil SR; Lyss AP; Loesch DM; Waterhouse DM; Bromund JL; Chen R; Hristova-Kazmierski M; Treat J; Obasaju CK; Marciniak M; Gill J; Schiller JH
J Clin Oncol; 2009 Feb; 27(4):591-8. PubMed ID: 19075278
[TBL] [Abstract][Full Text] [Related]
17. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
18. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
